Business
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clinical development strategy includes an mCRPC-dedicated Phase 1b trial in PLUVICTO®-naïve and -experienced patients, and a second Phase 1b basket trial in other B7-H3 expressing solid tumorsTwo-trial strategy enables evaluation of AKY-2519 in broader patient segments and efficient generation of indication-relevant data; preliminary mCRPC data expected in 2027 Aktis to hold conference call tomorrow, Tuesday, May 5, 2026, at 8 a.m. ET to discuss its clinical development strategy for AKY-2519 BOS
About this update from Aktis Oncology, Inc.
[{"type":"image","alt":"Aktis Oncology Inc.","displaySize":"","headline":null,"caption":"Aktis Oncology Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/ce6b69e12b45a12fae0c8794865a1a20"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AR6yxKnk8scSucJfH1hgMg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMA--/https://media.zenfs.com/en/globenewswire.com/ce6b69e12b45a12fae0c8794865a1a20","width":300,"height":150}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Clinical development strategy includes an mCRPC-dedicated Phase 1b trial in PLUVICTO®-naïve and -experienced patients, and a second Phase 1b basket trial in other B7-H3 expressing solid tumors","length":192,"tagName":"p"}]},{"val":[{"type":"text","content":"Two-trial strategy enables evaluation of AKY-2519 in broader patient segments and efficient generation of indication-relevant data; preliminary mCRPC data expected in 2027","length":171,"tagName":"p"}]},{"val":[{"type":"text","content":"Aktis to hold conference call tomorrow, Tuesday, May 5, 2026, at 8 a.m. ET to discuss its clinical development strategy for AKY-2519","length":137,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":500,"olType":false},{"type":"text","content":"BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, today announced the initiation of a Phase 1b clinical trial of AKY-25191 in patients with metastatic castration-resistant prostate cancer (mCRPC). The mCRPC-dedicated Phase 1b trial is part of Aktis’ clinical development strategy to develop AKY-2519 broadly in B7-H3 expressing tumors. Aktis plans to initiate a Phase 1b basket trial in lung, colorectal, and other high B7-H3 expressing solid tumors in the second half of 2026.","length":664,"tagName":"p"},{"type":"text","content":"“We see an opportunity to advance broad clinical development of AKY-2519 given the high expression of B7-H3 across multiple solid tumor types and associated poor prognosis. We are excited to advance a two-trial strategy, which enables us to evaluate AKY-2519 broadly in multiple patient subsets and to efficiently generate indication-relevan...